Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

88.45EUR
7:35pm IST
Price Change (% chg)

€-0.01 (-0.01%)
Prev Close
€88.46
Open
€88.81
Day's High
€88.85
Day's Low
€87.97
Volume
2,449,102
Avg. Vol
2,493,807
52-wk High
€88.85
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.54
Market Cap (Mil.): €117,214.10
Shares Outstanding (Mil.): 1,325.21
Dividend: 2.80
Yield (%): 3.17

Financials

  SASY.PA Industry Sector
P/E (TTM): 28.50 32.70 33.56
EPS (TTM): 3.10 -- --
ROI: 5.31 18.13 17.36
ROE: 7.69 18.84 18.23
Search Stocks

Sanofi unveils heart disease partnership with MyoKardia

PARIS - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

17 Sep 2014

Sanofi unveils heart disease partnership with MyoKardia

PARIS, Sept 17 - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

17 Sep 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - (This story corrects the Sept.11 story. In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara)

13 Sep 2014

CORRECTED-Sanofi aims to grow Genzyme unit with new drugs and acquisitions

(Corrects Sept.11 story. In 10th paragraph, quote should be attributed to Bill Sibold, not Mike Panzara)

13 Sep 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.

11 Sep 2014

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

11 Sep 2014

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS, Sept 11 - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

11 Sep 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS, Sept 11 - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.

11 Sep 2014

Lilly, Boehringer copy of Sanofi's insulin gets EU approval

- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.

10 Sep 2014

Euro's slide revives hopes of European corporate profits recovery

* Recent drop in euro to translate into 3-6 pct rise in earnings

05 Sep 2014

Earnings vs. Estimates

Search Stocks